Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[seek the light]

Something that is worth speculating on is the First disease that the company will file on in the clinical trial for phase 2. MY bet is IBS, because they can get a very high response rate in a short period of time, imo. I would not be at all surprised to see a 60-70% positive response within 60 days.

The beauty of treating IBS first is that Crohn's disease can be added in as a second indication in the same trial, maybe even a third indication of treating Diverticulitis. Combined treatment potential would be $8-10 billion. And very positive results on all three would have major pharmaceutical companies eager to do a JV deal.


Get this approved and I believe worrying over dilution will have been a waste of time and energy.